Kyle Doherty

Articles

Multitargeted DNA Test Bests Fecal Immunochemical Test With Higher Sensitivity for CRC

March 13th 2024

Higher sensitivity for CRC and advanced precancerous lesions, but lower specificity for advanced neoplasia, was seen with a next-generation stool DNA test vs a fecal immunochemical test.

Dual-Targeted CAR T-Cell Therapy Displays Early Efficacy in Recurrent Glioblastoma

March 13th 2024

A CAR T-cell therapy directed toward 2 brain tumor–associated proteins displayed preliminary activity in recurrent glioblastoma.

Heath Discusses Utility of NECTIN-4 as a Target in Urothelial Carcinoma

March 13th 2024

Elisabeth I. Heath, MD, FACP, discusses what makes NECTIN-4 an attractive target in drug development and the significance of the EV-302/KEYNOTE-A39 trial findings.

Emavusertib Progresses to Phase 2 Study in AML and MDS

March 12th 2024

The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.

Coming Full Circle

March 12th 2024

Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.

DREAMM-8 Produces Positive Topline Results in Relapsed/Refractory Multiple Myeloma

March 7th 2024

Belantamab mafodotin plus pomalidomide and dexamethasone extended PFS in relapsed/refractory multiple myeloma.

Adjuvant Chemotherapy After Nephroureterectomy Offers DFS Benefit in Upper Tract Urothelial Cancer

March 7th 2024

Patients with upper tract urothelial cancer who received adjuvant chemotherapy after nephroureterectomy experienced extended DFS vs those who received surveillance.

Randall Details Inaugural Birmingham Orthopedic Oncology Meeting

March 6th 2024

R. Lor Randall, MD, FACS, discusses the top takeaways from the inaugural 2024 Birmingham Orthopedic Oncology Meeting.

Porter Discusses FDA’s Call for Secondary Malignancies Boxed Warning on CAR T-Cell Therapies

March 5th 2024

David L. Porter, MD, discusses the decision by the FDA to call for a boxed warning for secondary malignancies on all approved CAR T-cell agents.

Banerjee Discusses FDA Call for Secondary Malignancies Boxed Warning on CAR T-cell Therapies

March 4th 2024

Rahul Banerjee, MD FACP, discusses the FDA’s decision to add a class-wide boxed warning for secondary malignancies on all approved CAR T-cell therapies.

SNB-101 Receives Orphan Drug Designation in Pancreatic Cancer

February 29th 2024

SNB-101, a novel polymer nanoparticle agent, has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

FDA Accepts BLA for First-Line Tislelizumab Plus Chemotherapy in Gastric/GEJ Cancer

February 27th 2024

The biologics license application for first-line tislelizumab plus chemotherapy for gastric/gastroesophageal junction cancer has been accepted by the FDA.

IO-202 Receives FDA Orphan Drug Designation for CMML

February 22nd 2024

The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.

FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy in Endometrial Cancer

February 20th 2024

The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA.

Lurbinectedin Displays Superior Risk/Benefit Ratio Over Topotecan in SCLC

February 20th 2024

Lurbinectedin demonstrated greater activity and a superior safety profile vs topotecan in a subset of small cell lung cancer.

UV1 Receives Orphan Drug Designation From EMA in Mesothelioma

February 19th 2024

The European Medicines Agency has granted orphan drug designation to UV1 in patients with mesothelioma.

FDA Grants Orphan Drug Designation to Tigilanol Tiglate in Soft Tissue Sarcoma

February 16th 2024

The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma.

BLA Resubmitted to FDA for Denileukin Diftitox in Relapsed/Refractory Cutaneous T-cell Lymphoma

February 14th 2024

The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.

The Ongoing Investigation of GLSI-100 Continues in the Flamingo-01 Study for HER2/Neu+ Breast Cancer

February 14th 2024

The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.

APEX-01 Looks to Add First PSMA-Directed ADC to Treatment Paradigm in mCRPC

February 13th 2024

John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.